Additional new data will show how Myriad’s second-generation tumor-informed molecular residual disease (MRD) assay demonstrated high sensitivity, specificity and measurement accuracy, which, together, ...
(NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive ...
Discussions about ethics are important in many aspects of health care but are especially critical when the health care includes genetic testing. There are several aspects of genetic testing that ...